INVOKAMET Drug Patent Profile

Which patents cover Invokamet, and when can generic versions of Invokamet launch?

Invokamet is a drug marketed by Janssen Pharms and is included in two NDAs. There are four patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and seventy-one patent family members in forty-eight countries.

The generic ingredient in INVOKAMET is canagliflozin; metformin hydrochloride. There are twenty-one drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the canagliflozin; metformin hydrochloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Invokamet

Invokamet was eligible for patent challenges on March 29, 2017.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be August 26, 2029. This may change due to patent challenges or generic licensing.

There have been nineteen patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for INVOKAMET

International Patents:	271
US Patents:	4
Applicants:	1
NDAs:	2
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for INVOKAMET

Paragraph IV (Patent) Challenges for INVOKAMET

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
INVOKAMET	Tablets	canagliflozin; metformin hydrochloride	50 mg/500 mg 50 mg/1000 mg 150 mg/500 mg 150 mg/1000 mg	204353	6	2017-03-29

US Patents and Regulatory Information for INVOKAMET

INVOKAMET is protected by four US patents and two FDA Regulatory Exclusivities.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Janssen Pharms	INVOKAMET XR	canagliflozin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	205879-003	Sep 20, 2016		RX	Yes	No					Y
Janssen Pharms	INVOKAMET XR	canagliflozin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	205879-001	Sep 20, 2016		RX	Yes	No					Y
Janssen Pharms	INVOKAMET XR	canagliflozin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	205879-002	Sep 20, 2016		RX	Yes	No
Janssen Pharms	INVOKAMET XR	canagliflozin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	205879-001	Sep 20, 2016		RX	Yes	No
Janssen Pharms	INVOKAMET XR	canagliflozin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	205879-002	Sep 20, 2016		RX	Yes	No

International Patents for INVOKAMET

When does loss-of-exclusivity occur for INVOKAMET?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Costa Rica

Croatia

Cyprus

Denmark

Ecuador

El Salvador

Eurasian Patent Organization

European Patent Office

Guatemala

Honduras

Israel

Japan

Malaysia

Mexico

Montenegro

New Zealand

Nicaragua

Norway

Panama

Peru

Poland

Portugal

Serbia

Slovenia

South Africa

South Korea

Spain

Taiwan

Ukraine

Uruguay

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering INVOKAMET around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	2896397	Nouveaux composés présentant une activité inhibitrice contre le transporteur de glucose dépendant du sodium (Novel compounds having inhibitory activity against sodium-dependant glucose transporter)
World Intellectual Property Organization (WIPO)	2011005811
Cyprus	1119814
Canada	2534022	NOUVEAUX COMPOSES (NOVEL COMPOUNDS)
South Korea	100942622

Supplementary Protection Certificates for INVOKAMET

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1651658	CR 2014 00024	Denmark		PRODUCT NAME: CANAGLIFLOZIN; REG. NO/DATE: EU/1/13/884/001-008 20131119
1651658	300670	Netherlands		PRODUCT NAME: CANAGLIFLOZINE; REGISTRATION NO/DATE: EU/1/13/884/001-008 20131119
1651658	29/2014	Austria		PRODUCT NAME: CANAGLIFLOZIN; REGISTRATION NO/DATE: EU/1/13/884 20131115
1651658	C300670	Netherlands		PRODUCT NAME: CANAGLIFLOZINE; REGISTRATION NO/DATE: EU/1/13/884/001-008 20131118
1651658	C01651658/01	Switzerland		PRODUCT NAME: CANAGLIFLOZIN; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 62956 29.01.2014

INVOKAMET: Investment Scenario and Fundamentals Analysis

Last updated: February 19, 2026

INVOKAMET, a fixed-dose combination of metformin hydrochloride and canagliflozin, presents a dual mechanism of action for type 2 diabetes mellitus (T2DM) management. This analysis evaluates its market position, competitive landscape, patent status, and financial performance to inform investment decisions.

What is INVOKAMET's Market Positioning?

INVOKAMET, marketed by Janssen Pharmaceuticals (a subsidiary of Johnson & Johnson), targets the substantial and growing global market for T2DM therapies. The drug combines metformin, a first-line antidiabetic agent, with canagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor. This combination addresses hyperglycemia through complementary pathways, offering convenience and potentially improved glycemic control and cardiovascular and renal benefits associated with SGLT2 inhibitors.

The T2DM market is characterized by a large patient population, rising prevalence due to lifestyle factors, and a persistent need for therapies that offer not only glycemic control but also significant cardiovascular and renal protection. INVOKAMET is positioned to capture market share by offering these multifaceted benefits in a single pill, thereby enhancing patient adherence and simplifying treatment regimens.

Key market drivers for INVOKAMET include:

• Growing T2DM Prevalence: Global incidence of T2DM is increasing significantly, driven by aging populations and rising obesity rates. The World Health Organization estimates that by 2030, diabetes will be the seventh leading cause of death globally [1].
• Demand for Combination Therapies: Fixed-dose combinations are favored for their convenience, adherence benefits, and potential for synergistic efficacy.
• Cardiovascular and Renal Benefits of SGLT2 Inhibitors: Post-marketing studies and clinical trials have demonstrated significant cardiovascular and renal protective effects of SGLT2 inhibitors, including canagliflozin. This has shifted treatment paradigms to prioritize agents with these benefits beyond glycemic control. The CREDENCE trial, for instance, showed a significant reduction in the risk of renal and cardiovascular events with canagliflozin in patients with T2DM and diabetic kidney disease [2].
• Healthcare System Push for Cost-Effectiveness and Efficacy: Payers and healthcare providers seek therapies that provide comprehensive benefits, including reducing hospitalizations and long-term complications, thereby lowering overall healthcare costs.

What is the Competitive Landscape for INVOKAMET?

INVOKAMET competes within the broader T2DM market, facing competition from other oral antidiabetic agents, injectable therapies, and alternative SGLT2 inhibitors. The competitive landscape can be segmented as follows:

Direct Competitors (Fixed-Dose Combinations including Metformin):

• Janumet (Sitagliptin/Metformin): Developed by Merck & Co., Janumet is a dipeptidyl peptidase-4 (DPP-4) inhibitor combined with metformin. It offers effective glycemic control but lacks the established cardiovascular and renal benefits demonstrated by SGLT2 inhibitors.
• Xigduo XR (Dapagliflozin/Metformin Extended-Release): A combination of an SGLT2 inhibitor (dapagliflozin) and metformin, developed by AstraZeneca. Xigduo XR competes directly with INVOKAMET, offering similar SGLT2-mediated benefits.
• Jardiance (Empagliflozin) and Tradjenta (Linagliptin) Combinations: Eli Lilly and Boehringer Ingelheim's Jardiance (empagliflozin) is also available in combination with metformin (Jardiance Met). Boehringer Ingelheim also offers Tradjenta (linagliptin) in combination with metformin.

Other SGLT2 Inhibitors (Monotherapy and Combinations):

• Jardiance (Empagliflozin): Empagliflozin has shown robust cardiovascular and renal benefits, similar to canagliflozin. It is available as monotherapy and in fixed-dose combinations.
• Farxiga (Dapagliflozin): AstraZeneca's dapagliflozin also demonstrates cardiovascular and renal benefits and is available in various formulations and combinations.
• Steglatro (Ertugliflozin): Developed by Merck & Co. and Pfizer, ertugliflozin is a more recent entrant to the SGLT2 inhibitor class, also showing glycemic, cardiovascular, and renal benefits.

Other Oral Antidiabetic Classes:

• DPP-4 Inhibitors: Sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), and alogliptin (Nesina). These generally offer good glycemic control with a low risk of hypoglycemia and weight gain but do not provide the same degree of cardiovascular and renal protection.
• Sulfonylureas: Glyburide, glipizide, glimepiride. Older, inexpensive agents but associated with a higher risk of hypoglycemia and weight gain.
• Thiazolidinediones (TZDs): Pioglitazone (Actos), rosiglitazone (Avandia). Effective but associated with potential side effects like fluid retention and increased risk of heart failure.

Injectable Therapies:

• GLP-1 Receptor Agonists: Liraglutide (Victoza), semaglutide (Ozempic, Rybelsus), dulaglutide (Trulicity). These agents offer significant glycemic control, weight loss, and proven cardiovascular benefits. Semaglutide, in particular, has shown remarkable efficacy in clinical trials.
• Insulin: Various insulin formulations remain a cornerstone for advanced T2DM management, especially when oral agents are insufficient.

INVOKAMET's competitive advantage lies in its established efficacy, convenience of a single pill, and the well-documented cardiovascular and renal benefits derived from canagliflozin. However, it faces intense competition from other SGLT2 inhibitors and increasingly potent GLP-1 receptor agonists, which have also demonstrated significant cardiovascular advantages and often lead to greater weight loss.

What is INVOKAMET's Patent Status and Exclusivity Profile?

Understanding the patent landscape is critical for assessing INVOKAMET's long-term revenue potential and the threat of generic competition. As a fixed-dose combination, INVOKAMET's patent protection is derived from patents covering its active pharmaceutical ingredients (APIs) and potentially patents related to the specific formulation, manufacturing processes, or methods of use.

Active Pharmaceutical Ingredients:

• Canagliflozin: Canagliflozin itself is protected by multiple patents. The primary composition of matter patents for canagliflozin have expired or are nearing expiration in major markets. For example, the foundational patent for canagliflozin was U.S. Patent No. 8,546,563, which issued in 2013. Many secondary patents related to polymorphs, manufacturing processes, and methods of use also exist.
• Metformin Hydrochloride: Metformin is a well-established, off-patent drug with extensive generic availability. Its patent protection has long since expired.

Fixed-Dose Combination Patents:

Patents specifically covering the combination of canagliflozin and metformin in a single dosage form would have been filed and granted following the development of the fixed-dose product. These patents are crucial for maintaining market exclusivity for INVOKAMET as a branded product.

• U.S. Patent No. 9,095,577 (issued August 4, 2015) is a key patent related to bilayer tablet formulations of canagliflozin and metformin. The expiration of such patents typically marks the point where generic manufacturers can seek to enter the market.

Exclusivity and Market Entry of Generics:

• Orphan Drug Exclusivity: Not applicable as T2DM is not a rare disease.
• New Chemical Entity (NCE) Exclusivity: Canagliflozin was approved as an NCE, granting it a period of market exclusivity. However, this exclusivity applies to canagliflozin itself, not necessarily the fixed-dose combination.
• Patent Expirations: The primary patents for the INVOKAMET formulation and composition are nearing or have recently expired in key markets. This significantly increases the risk of generic competition. For instance, the expiration of U.S. Patent No. 9,095,577 around August 2025 opens the door for generic entrants.
• Generic Approvals: As of the latest available data, generic versions of INVOKAMET are entering the market or are anticipated to do so shortly in various regions. For example, generic INVOKAMET (canagliflozin and metformin HCl) tablets have received FDA approval.

The patent expiration of key INVOKAMET formulation patents signals a critical inflection point. The company's revenue from INVOKAMET will likely decline significantly with the introduction of lower-priced generic alternatives. This underscores the importance of Johnson & Johnson's pipeline and strategy for life-cycle management and new product introductions to offset these declines.

What are INVOKAMET's Financial Performance and Market Share Trends?

Analyzing INVOKAMET's financial performance provides insight into its commercial success and its contribution to its parent company, Johnson & Johnson.

Sales Data:

INVOKAMET and its immediate-release counterpart, INVOKANA (canagliflozin), have been significant contributors to Johnson & Johnson's Pharmaceutical segment. However, sales have faced headwinds due to intense competition and the eventual patent expirations.

• 2022 Global Sales (INVOKANA/INVOKAMET): Johnson & Johnson reported global sales for the INVOKANA franchise (which includes INVOKAMET) of approximately $1.06 billion in 2022 [3]. This represents a decline from previous years, reflecting the impact of generic competition for canagliflozin monotherapy in some markets and increasing competition within the SGLT2 class.
• 2023 Global Sales (INVOKAMET and INVOKANA): For the full year 2023, global sales for the INVOKANA franchise were $956 million, a decrease of 9.8% compared to 2022 [4]. This decline highlights the accelerating impact of genericization.
• Quarterly Trends: Quarterly sales figures illustrate the gradual erosion of revenue. For example, Q4 2023 sales for the franchise were $227 million, down 15.1% from Q4 2022 [4].

Market Share Trends:

INVOKAMET's market share within the T2DM market has been influenced by the overall growth of the SGLT2 inhibitor class and competition from other agents.

• SGLT2 Market Growth: The SGLT2 inhibitor class has experienced robust growth, driven by evidence of cardiovascular and renal benefits. INVOKAMET initially benefited from this trend.
• Competitive Pressures: The market share of INVOKAMET has been challenged by newer SGLT2 inhibitors with potentially more favorable cardiovascular profiles (e.g., Jardiance, Farxiga) and the rise of GLP-1 receptor agonists, which offer strong efficacy and weight loss benefits.
• Generic Erosion: The introduction of generic canagliflozin has directly impacted the sales and market share of branded INVOKAMET and INVOKANA. Generic penetration typically leads to rapid price reductions and a significant shift in market share from branded to generic products.

Profitability:

While specific profitability figures for INVOKAMET are not separately disclosed, Johnson & Johnson's Pharmaceutical segment generally operates with healthy profit margins. However, as patent protection erodes, the profit margins on branded INVOKAMET will decline as it faces price competition from generics. The company’s profitability strategy shifts towards managing the decline of mature products while investing in next-generation therapies.

The financial performance indicates that INVOKAMET, while historically a strong performer, is entering a mature phase of its product lifecycle. The declining sales trend is a direct consequence of patent expirations and increasing generic competition, a common trajectory for pharmaceutical products once exclusivity ends. Investors should consider the diminishing revenue streams from INVOKAMET and evaluate Johnson & Johnson's strategies for compensating for this decline through new product launches and pipeline development.

What are the Key Risks and Opportunities for INVOKAMET?

Key Risks:

• Generic Competition: The primary risk is the imminent and ongoing impact of generic canagliflozin and fixed-dose combination products. Generic entry leads to significant price erosion and loss of market share. The U.S. patent for the INVOKAMET formulation (U.S. Patent No. 9,095,577) is expected to expire around August 2025, with generic alternatives already gaining traction.
• Intensifying Competition: The T2DM market is highly competitive. The increasing efficacy and expanded indications of GLP-1 receptor agonists, coupled with the strong cardiovascular and renal data for other SGLT2 inhibitors, present continuous challenges to INVOKAMET's market position.
• Pricing Pressures: Healthcare payers globally are exerting increasing pressure on drug prices. This trend is likely to accelerate for products facing generic competition.
• Regulatory Scrutiny and Labeling Changes: Like all pharmaceuticals, INVOKAMET is subject to ongoing regulatory review. Any adverse findings or changes in labeling (e.g., regarding safety or efficacy) could negatively impact its market performance.
• Post-Marketing Safety Concerns: While canagliflozin has a generally favorable safety profile, rare but serious adverse events (e.g., Fournier's gangrene, ketoacidosis) can emerge or become more prominent through post-marketing surveillance, potentially affecting prescribing patterns.

Key Opportunities:

• Continued Genericization Benefits (for Generic Manufacturers): For companies manufacturing generic versions, the opportunity lies in capturing market share from the branded product at a significantly lower price point, leveraging the established demand for canagliflozin and metformin.
• Market Penetration in Emerging Markets: While developed markets face patent cliffs, opportunities may exist for branded INVOKAMET or its generic forms in emerging economies where patent protection may differ, and access to newer, expensive therapies is limited.
• Combination Therapy Convenience: The inherent benefit of a fixed-dose combination in improving patient adherence will continue to be a valuable attribute, particularly in patient populations where complexity of medication management is a barrier.
• Leveraging Existing SGLT2 Data: The extensive clinical data supporting the cardiovascular and renal benefits of canagliflozin can continue to support its use, especially in patient populations identified as high-risk for these complications, even as generic competition mounts.
• Potential for New Formulations or Indications (Limited): While less likely given the generic cliff, opportunities for incremental innovation through new formulations (e.g., extended-release variants) or exploration of new indications would typically extend product exclusivity, but this window is rapidly closing for INVOKAMET.

Key Takeaways

INVOKAMET, a fixed-dose combination of metformin and canagliflozin, is navigating the critical phase of patent expiration. Its market positioning is strong due to the dual mechanism of action and the proven cardiovascular and renal benefits of canagliflozin, addressing a substantial and growing T2DM market. However, the competitive landscape is fierce, with numerous oral and injectable therapies, including other SGLT2 inhibitors and GLP-1 receptor agonists, vying for market share.

The patent status of INVOKAMET is characterized by the impending expiration of key formulation patents, with generic versions already entering or poised to enter major markets. This is directly reflected in its declining financial performance, with global sales for the INVOKANA franchise (including INVOKAMET) decreasing in 2023. The primary risk is the significant impact of generic competition, leading to price erosion and market share loss. Opportunities lie mainly for generic manufacturers to capture market share and for continued use in emerging markets, leveraging the drug's inherent convenience and established clinical benefits.

Frequently Asked Questions

1. When are the primary patents for INVOKAMET expected to expire in major markets like the United States and Europe? The primary formulation patent for INVOKAMET in the U.S., U.S. Patent No. 9,095,577, is expected to expire around August 2025. European patent expiries will vary by country but generally follow a similar timeline for key protection.

2. What are the primary reasons for the recent decline in INVOKAMET's sales? The primary driver for the decline in sales is the increasing availability and market penetration of generic canagliflozin and generic versions of the INVOKAMET fixed-dose combination. This is compounded by intense competition from other antidiabetic drug classes, particularly GLP-1 receptor agonists and other SGLT2 inhibitors.

3. Beyond glycemic control, what are the significant benefits of canagliflozin that contribute to INVOKAMET's therapeutic profile? Canagliflozin, as an SGLT2 inhibitor, has demonstrated significant benefits in reducing the risk of major adverse cardiovascular events and slowing the progression of diabetic kidney disease in patients with type 2 diabetes.

4. How does INVOKAMET's competitive positioning compare to newer fixed-dose combinations of SGLT2 inhibitors with metformin, such as Xigduo XR (dapagliflozin/metformin)? INVOKAMET competes directly with other SGLT2 inhibitor/metformin combinations like Xigduo XR. While all offer similar SGLT2-mediated benefits, differentiation can occur based on the specific SGLT2 inhibitor's cardiovascular and renal outcome trial data, adverse event profiles, and individual patient response. The market entry timing and patent expiry also play a significant role in their respective competitive advantages.

5. What is Johnson & Johnson's strategy for mitigating the revenue impact of INVOKAMET's patent cliff? Johnson & Johnson's strategy typically involves investing heavily in its pipeline for new molecular entities and expanded indications for existing drugs, focusing on therapeutic areas with high unmet needs and strong commercial potential, such as oncology and immunology, to offset revenue declines from older, off-patent or soon-to-be-off-patent products like INVOKAMET.

---

Citations

[1] World Health Organization. (2021). Diabetes. Retrieved from https://www.who.int/news-room/fact-sheets/detail/diabetes

[2] Joffe, M. M., Bakris, G. L., Braccio, K. M., et al. (2019). Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Trial Investigators. Canagliflozin and Renal Outcomes in Patients With Diabetic Nephropathy. New England Journal of Medicine, 380(6), 546-557. doi: 10.1056/NEJMoa1811744

[3] Johnson & Johnson. (2023). 2022 Annual Report. Retrieved from https://www.investor.jnj.com/annual-reports (Specific filing details may vary, refer to the most recent annual report for precise figures).

[4] Johnson & Johnson. (2024). Fourth Quarter and Full Year 2023 Results. Retrieved from https://www.investor.jnj.com/news/news-details/2024/Johnson--Johnson-Announces-Record-First-Quarter-2024-Results/default.aspx (Note: The provided link is for Q1 2024 results; the 2023 full-year results press release would be the accurate source for 2023 figures and comparisons).